Overview

A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

Patients with HCC with portal vein involvement not involving the bifurcation (vP1-vP3) and no evidence of extra-hepatic spread will be enrolled. Patients will be required to have Child's A liver function and no significant portal hypertension. Patients will be randomly assigned with a 1:1 ratio to either surgery followed by adjuvant sorafenib or sorafenib alone. Patients will be followed by serial imaging. The primary end-point is overall survival.

Phase:

Phase 2

Details

Lead Sponsor:

White Plains Hospital

Collaborators:

Anhui Provincial Hospital
Cancer Hospital of Guangxi Medical University
Eastern Hepatobiliary Surgery Hospital
Fujian Cancer Hospital
Sun Yat-sen University
Wenzhou People's Hospital
Wenzhou People’s Hospital
West China Hospital

Treatments:

Sorafenib